Physician profile
Heidi E Shields
NPI 1053406488
$331.81
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $62.69 · 2022: $15.75.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $61.18 | 2019-2020 | |
| Pfizer INC. | $40.84 | 2019 | |
| Supernus Pharmaceuticals, INC. | $36.86 | 2019-2020 | |
| Novo Nordisk INC | $34.70 | 2019 | |
| Janssen Pharmaceuticals, INC | $34.41 | 2019 | |
| Lilly USA, LLC | $27.25 | 2019 | |
| Merck Sharp & Dohme LLC | $25.82 | 2019 | |
| Insulet Corporation | $16.39 | 2019 | |
| Abbott Laboratories | $15.75 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $13.37 | 2020 | |
| Glaxosmithkline, LLC. | $12.67 | 2019 | |
| Astellas Pharma US INC | $12.57 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Shields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.